Inhibitors of bruton's tyrosine kinase

Details Inhibitors of bruton's tyrosine kinase Inhibitors of bruton's tyrosine kinase

2007-12-26

2010-11-02

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S350000

Reexamination Certificate

active

07825118

ABSTRACT:
Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

REFERENCES:
patent: 6326469 (2001-12-01), Ullrich et al.
patent: 6506769 (2003-01-01), Snow et al.
patent: 6660744 (2003-12-01), Hirst et al.
patent: 6753348 (2004-06-01), Uckun et al.
patent: 6770639 (2004-08-01), Snow et al.
patent: 6921763 (2005-07-01), Hirst et al.
patent: 2003/0040461 (2003-02-01), McAtee
patent: 2003/0125235 (2003-07-01), Foxwell
patent: 2004/0006083 (2004-01-01), Hirst et al.
patent: 2005/0008640 (2005-01-01), Waegell et al.
patent: 2005/0090499 (2005-04-01), Currie et al.
patent: 2005/0101604 (2005-05-01), Currie et al.
patent: 2005/0196851 (2005-09-01), Uckun
patent: 2005/0209255 (2005-09-01), Jimenez et al.
patent: 2006/0079494 (2006-04-01), Santi et al.
patent: 2006/0167090 (2006-07-01), Uckun et al.
patent: 2008/0076921 (2008-03-01), Honigberg et al.
patent: 2008/0108636 (2008-05-01), Honigberg et al.
patent: 2009/0181987 (2009-07-01), Honigberg
patent: 2010/0004270 (2010-01-01), Honigberg
patent: 2010/0022561 (2010-01-01), Honigberg
patent: 2010/0041677 (2010-02-01), Honigberg
patent: WO-97-28161 (1997-08-01), None
patent: WO-00-56737 (2000-09-01), None
patent: WO-01-19829 (2001-03-01), None
patent: WO-01-19829 (2001-03-01), None
patent: WO-01-25238 (2001-04-01), None
patent: WO-01-41754 (2001-06-01), None
patent: WO-01-44258 (2001-06-01), None
patent: WO-02-38797 (2002-05-01), None
patent: WO-02-080926 (2002-10-01), None
patent: WO-03-000187 (2003-01-01), None
patent: WO-2004-096253 (2004-11-01), None
patent: WO-2004-100868 (2004-11-01), None
patent: WO-2004-100868 (2004-11-01), None
patent: WO-2005-005429 (2005-01-01), None
patent: WO-2005-014599 (2005-02-01), None
patent: WO-2008-054827 (2008-05-01), None
Arnold, L.D. et al., “Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of lck 1,” Bioorg. Med. Chem. Ltrs. 10:2167-2170 (2000).
Browning, J.L., “B cells move to centre stage: novel opportunities for autoimmune disease treatment”, Nature Reviews/Drug Discovery vol. 5, Jul. 2006, pp. 564-576.
Burchat et al., “Pyrazolo[3,4-d]pyrimidines Containing an Extended 3-Substituent as Potent Inhibitors of Lck—a Selectivity Insight,” Bioorg. Med. Chem. Ltrs. 12:1687-1690 (2002).
Cohen, M.S. et al., “Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors,” Science, vol. 308, May 27, 2005, pp. 1318-1321.
Desiderio, S., “Role of Btk in B cell development and signaling,” Curr. Op. in Immunology 1997, 9:534-540.
Fruman, D.A., “Xid-like Phenotypes: A B Cell Signalosome Takes Shape,” Immunity 13:1-3 (Jul. 2000).
Gold, Michael R., “To make antibodies or not:signaling by the B-cell antigen receptor,” Trends in Pharmacological Sciences, 23(7):316-324 (Jul. 2002).
Horwood, Nicole J. et al., “Bruton's Tyrosin Kinase Is Required for Lipopolysaccharide—induced Tumor Necrosis Factor α Production,” J. Exp. Med. 197(12):1603-1611 (Jun. 2003).
Iwaki, Shoki et al., “Btk Plays a Crucial Role in the Amplification of FceRI-mediated Mast Cell Activation by Kit,” J. Biol. Chem. 280(48):40261-40270 (Dec. 2, 2005).
Jefferies, Caroline A. et al., “Bruton's Tyrosine Kinase Is a Toll/Interleukin-1 Receptor Domain-binding Protein That Participates in Nuclear Factor {acute over (κ)}B Activation by Toll-like Receptor 4,” J. Biol. Chem. 278:26258-26264 (2003).
Kawakami, Yuko et al., “Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase,” PNAS USA 96:2227-2232 (1999).
Kuppers, R., “Mechanisms of B-cell lymphoma pathogenesis,” Nature Reviews/Cancer, vol. 5, Apr. 2005, pp. 251-262.
Kurosaki, Tomohiro, “Functional dissection of BCR signaling pathways,” Curr. Op. Imm. 12:276-281 (2000).
Mahajan, S. et al., “Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (BTK), LFM-A13 [α-Cyano-β-Methyl-N-(2,5-Dibromophenyl)Propenamide],” J. of Biol. Chem., vol. 274, No. 14, Apr. 2, 1999, pp. 9587-9599.
Mangla, Anita et al., “Pleiotropic consequences of Bruton tyrosin kinase deficiency in myeloid lineages lead to poor inflammatory responses,” Blood 104(4):1191-1197 (2004).
Niiro, Hiroaki and Clark, Edward A., “Regulation of B-Cell Fate by Antigen-Receptor Signals,” Nature Reviews 2:945-956 (2002).
Nisitani, S. et al., “In situ detection of activated Bruton's tyrosine kinase in the Ig signaling complex by phosphopeptide-specific monoclonal antibodies,” PNAS USA 96:2221-2226 (1999).
Oligino, Thomas J. and Dalrymple, Stacie A., “Targeting B cells for the treatment of rheumatoid arthritis,” Arthirits Res Ther 5(Suppl.4):S7-S11 (2002).
Pan, Z. et al., “Discovery of Selectable Irreversible Inhibitors for Bruton's Tyrosine Kinase,” ChemMedChem 2006, 1, 1-5.
Quek, L.S. et al., “A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen,” Curr. Biol. 8(20):1137-1140 (1998).
Sada, Kiyonao and Yamamura, Hirohei, “Protein-Tyrosine Kinases and Adaptor Proteins in FceRI-Mediated Signaling in Mast Cells,” Curr. Mol. Med. 3(1):85-94 (2003).
Schaeffer, Edward M. and Schwartzberg, Pamela L., “Tec family kinases in lymphocyte signaling and function,” Curr. Op. Imm. 12:282-288 (2000).
Science IP CAS Search, Sep. 5, 2006.
Science IP CAS Search, Mar. 16, 2006.
Merged Markush Service Search, Jun. 27, 2005.
Shaffer, A.L. et al., Lymphoid malignancies: the dark side of B-cell differentiation, Nature Reviews/Immunology, vol. 2, Dec. 2002, pp. 920-932.
Smaill, J.B. et al., “Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(Phenylamino)prido[d]pyrimidine Acrylamides as Irresversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor,” J. Med. Chem. 42(10):1803-1815 (1999).
Smith, C.I. Edvard et al., “The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species,” BioEssays 23:436-446 (2001).
Smolen, Josef S. and Steiner, Gunter, “Therapeutic Strategies for Rheumatoid Arthritis,” Nature Reviews 2:473-488 (2003).
Uckun, Fatih M. et al., “The Anti-leukemic Bruton's Tyrosin Kinase Inhibitor αcyano-β-hydroxy-β-mehyl-N-(2,5-dibromophenyl)Propenamide (LFM-A13)Prevents Fatal Thromboembolism,” Leuk. Lymphoma 44(9):1569-1577 (2003).
Uckun, Fatih M. et al., “In Vivo Pharmacokinetic Features, Toxicity Profile, and Chemosensitizing Activity of α-Cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a Novel Antileukemic Agent Targeting Bruton's Tyrosine Kinase,” Clin. Cancer Res. 8:1224-1233 (2002).
Uckun, F.M., “Bruton's Tyrosin Kinase (BTK) as a Dual-Function Regulator of Apoptosis,” Biochem. Pharmacology, vol. 56, pp. 683-691, 1998.
Uckun, Fatih M. et al., “BTK as a Mediator of Radiation-Induced Apoptosis in DT-40 Lymphoma B Cells,”Science vol. 273 No. 5278, pp. 1096-1100 (1996).
Vassilev, A.O. and Uckun, F.M., “Therapeutic Potential of Inhibiting Bruton's Tyrosine Kinase, (BTK),” Current Pharmaceutical Design, 2004, 10, 1757-1766.
Vassilev,Alexei et al., “Bruton's Tyrosine Kinase as an Inhibitor of the Fas/CD95 Death-inducing Signaling Complex,” J. Biol. Chem. 274(3):1646-1656 (1999).
Yamamoto, Noriyuki et al., “The Orally Available Spleen Tyro

Affiliated with

Also associated with

Rating

Inhibitors of bruton's tyrosine kinase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of bruton's tyrosine kinase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of bruton's tyrosine kinase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4249910